Zhongzhi Pharmaceutical Holdings Ltd. has issued a profit warning, indicating a significant decline in its financial performance for the first half of 2025. The company anticipates a decrease in net profit of approximately 90% compared to the same period in the previous year. This downturn is attributed to adjustments in industry policies that have led to a short-term drop in sales revenue, subsequently affecting profitability. Despite these challenges, the company remains committed to market investment and is actively seeking new business growth opportunities. Shareholders and potential investors are advised to exercise caution when dealing with the company's shares and to await the publication of the full unaudited consolidated results by the end of August 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.